{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-26-000027","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.737619+00:00","generated_at":"2026-05-14T21:51:17.936266+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Entrada reports positive Phase 1/2 data for ENTR-601-44 in DMD; Q1 net loss $39.7M","bullets":["Cohort 1 of ELEVATE-44-201 met primary safety endpoint: no SAEs, no discontinuations, kidney markers normal.","Statistically significant improvement in Time to Rise velocity versus placebo (p<.05), 3.5x MCID threshold.","Dystrophin increased 2.36% over 4.00% baseline; exon skipping increased 2.31% over 2.66% baseline.","Cash, cash equivalents and marketable securities $254.9M as of March 31, 2026; runway into Q3 2027.","Q1 net loss $39.7M vs $17.3M in Q1 2025; collaboration revenue dropped to $0.9M from $20.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-26-000027","json":"https://secwatch.observer/filing/0001689375-26-000027.json","markdown":"https://secwatch.observer/filing/0001689375-26-000027.md","text":"https://secwatch.observer/filing/0001689375-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/0001689375-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/trda-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:51:17.936266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28c02a1c2b049c461c077206073ca16164c03738","claim":"Entrada Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 7, 2026, Entrada Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and other corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/0001689375-26-000027-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}